Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,130 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 0.9 Normal Saline Clear all

Conditions: Head Lice
Interventions: Abametapir Lotion 0.74% w/w, 0.1% sodium lauryl sulfate, saline 0.9%, Vehicle Lotion; Drug · Other
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years and older
Enrollment: 238 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Paramus, New Jersey

Conditions: Prostate Cancer, Localized Prostate Carcinoma
Interventions: Leuprolide, Degarelix, Relugolix, Triptorelin, Bicalutamide, 18-F Flotufolastat PSMA PET, Radical prostatectomy; Drug · Diagnostic Test · Procedure
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: OPT101; Drug
Lead sponsor: Op-T LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Centennial, Colorado

Conditions: Healthy Volunteers
Interventions: NCTX (PEGylated Liposomal Iodixanol Injection), Saline Placebo; Drug
Lead sponsor: Marval Pharma Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Depression
Interventions: Ketamine Hydrochloride, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 99 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Diltiazem Skin Sensitivity.
Interventions: Diltiazem Hydrochloride 2% Cream, Vehicle Cream, 0.1% solution of sodium lauryl sulfate (SLS), Saline (0.9%); Drug
Lead sponsor: Ventrus Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Paramus, New Jersey

Conditions: Myofacial Pain, Pain, Neck, Pain, Back, Cervical Fusion
Interventions: Trigger point injection with bupivacaine, Trigger point injection with normal saline, Lidocaine skin wheal; Drug
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Trigeminal Neuralgia
Interventions: OnabotulinumtoxinA 100 UNT [Botox], Sodium Chloride 0.9% for Injection, Preservative Free; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Anaplastic Large Cell Lymphoma
Interventions: Pralatrexate Injection, Bexarotene Capsules, Vitamin B12, Folic Acid; Drug · Dietary Supplement
Lead sponsor: Acrotech Biopharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 4
States / cities: Stanford, California • New York, New York • Pittsburgh, Pennsylvania + 1 more

Conditions: Glabellar Frown Lines
Interventions: Botulinum toxin, Type A, 0.9% sterile, unpreserved saline; Biological · Other
Lead sponsor: Evolus, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Osteoarthritis of the Knee
Interventions: TLC599, DSP, Normal Saline; Drug · Other
Lead sponsor: Taiwan Liposome Company; Industry
Eligibility: 40 Years and older
Enrollment: 504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 41
States / cities: Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 33 more

Conditions: Acute Pain
Interventions: Arginine vasopressin, Saline, Observational learning, fMRI data aquisition; Drug · Other · Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Postoperative Pain, Bunions
Interventions: HTX-011A, Saline Placebo, HTX-011B, HTX-002, Bupivacaine HCl, HTX-009; Drug · Biological
Lead sponsor: Heron Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 5
States / cities: Anaheim, California • Bakersfield, California • Pasadena, Maryland + 2 more

Conditions: Clostridium Difficile Associated Disease
Interventions: Clostridium difficile vaccine, placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 1,317 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 24
States / cities: Mobile, Alabama • Redding, California • Coral Gables, Florida + 20 more

Conditions: Stress Urinary Incontinence
Interventions: Bupivacaine, Saline, Epinephrine; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Hypersensitivity
Interventions: KeraStat® Cream, KeraStat Gel, Biafine, Histamine, Saline (0.9% NaCl); Device · Drug
Lead sponsor: KeraNetics, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Healthy
Interventions: granisetron; Drug
Lead sponsor: Kyowa Kirin Co., Ltd.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Healthy
Interventions: Clinical Center Reference Endotoxin (CCRE), Normal saline; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 50 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Ovarian Cancer
Interventions: Farletuzumab, Carboplatin, Taxane, Farletuzumab-matched placebo; Drug
Lead sponsor: Morphotek; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 110
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 91 more

Conditions: Posttraumatic Stress Disorder
Interventions: Neuropeptide Y; Drug
Lead sponsor: James Murrough; Other
Eligibility: 18 Years to 60 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Knee Osteoarthritis
Interventions: Micronized DHACM 40 mg, Micronized DHACM 100 mg, Saline; Biological · Drug
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 14
States / cities: La Mesa, California • Miami, Florida • The Villages, Florida + 9 more

Conditions: Fever
Interventions: Ibuprofen, Normal Saline; Drug · Other
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 8
States / cities: Orlando, Florida • St Louis, Missouri • Greensboro, North Carolina + 4 more

Conditions: Cytomegalovirus
Interventions: mRNA-1647, Placebo; Biological · Other
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 9 Years to 25 Years
Enrollment: 873 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 44
States / cities: La Mesa, California • Sacramento, California • Fort Collins, Colorado + 38 more

Conditions: Wrinkles in Decolletage, Pigmentation, Décolleté Wrinkles
Interventions: KB304, 0.9% Normal Saline (NS); Biological · Drug
Lead sponsor: Krystal Biotech, Inc.; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Newport Beach, California

Search by objective public record fields.

Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.

Single Dose Safety, Tolerability and Pharmacokinetic Study of NCTX in Healthy Volunteers

A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients

Topical Safety Study of Topical Diltiazem Hydrochloride

Trigger Point Injections in Anterior Cervical Surgery

OnabotulinumtoxinA for Trigeminal Neuralgia

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001

Extended and Controlled Release Liposomal Formulated Dexamethasone for Chronic Knee OA Pain

Vasopressin and Pain Perception in the Brain

Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy

Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age

Voiding Function After Mid-Urethral Slings With and Without Local Anesthetic: Randomized Controlled Trial

Skin Prick Test of KeraStat® Cream

Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS)

Effects of 20,000 EU of Clinical Center Reference Endotoxin (CCRE) Versus Placebo(ENDOHEART)

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

A Dose Escalation Study of Intranasal Neuropeptide Y in Post Traumatic Stress Disorder (PTSD)

Phase 2B Micronized DHACM vs. Saline in the Treatment of Knee Osteoarthritis

Efficacy, Safety, and Pharmacokinetics of Intravenous Ibuprofen in Adult Febrile Patients

A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

A Study Assessing KB304 for the Treatment of Wrinkles in Women